Veru Inc. (VERU) — FY2020 Form 10-K
Business context and reporting period. This is an annual report for the fiscal year ended September 30, 2020, not a standalone fourth-quarter report; separate Q4 financial results are not provided in the supplied filing text. Veru is developing oncology medicines for prostate and breast cancers, while its Sexual Health Business—primarily FC2 female condoms—generated most revenue and helped fund development. The financial statements received an unqualified audit opinion.
Key financial metrics
| Metric | FY2020 | FY2019 |
|---|---|---|
| Net revenue | $42.6 million | $31.8 million |
| Gross profit / margin | $30.8 million / 72% | $21.7 million / 68% |
| Operating loss | $14.7 million | $6.4 million |
| Net loss | $19.0 million | $12.0 million |
| Net loss per diluted share | $0.28 | $0.19 |
| Cash from operating activities | $(1.9) million | $(5.5) million |
| Cash and cash equivalents at year-end | $13.6 million | $6.3 million |
| Working capital at year-end | $12.3 million | $2.8 million |
- Revenue mix: FC2 generated $40.6 million, or about 95% of total revenue; PREBOOST generated $2.0 million. FC2 U.S. prescription revenue was $27.1 million, versus $13.4 million from the global public-health sector.
- Liquidity and debt: At September 30, 2020, the balance sheet reported a $5.8 million net SWK credit-agreement liability, classified as current, and a $6.7 million residual royalty liability, including $1.1 million current. Management estimated approximately $7.3 million of credit-agreement payments and $1.1 million of residual royalty payments during the following 12 months. The SWK facility requires payments based on FC2 revenue and is secured by FC2-related assets.
- Cash flows and financing: Investing activities used $0.1 million. Financing activities provided $9.3 million, including $13.4 million from Aspire Capital share sales, partly offset by $4.4 million of SWK principal payments. Cash from operations improved year over year, while the net loss widened.
Material changes versus FY2019
- Revenue increased 34%, while gross margin rose from 68% to 72%. FC2 revenue grew 31% despite total FC2 unit sales falling 14% to 32.8 million units; average selling price per unit rose 52%, principally because the higher-priced U.S. prescription channel made up a larger share of sales.
- U.S. prescription FC2 revenue increased 93%; global public-health FC2 revenue declined 20%, reflecting order and tender timing. U.S. prescription sales represented about 64% of total revenue, compared with 44% in FY2019.
- Net loss increased by $7.0 million. FY2020 included a $14.1 million noncash impairment of acquired in-process research and development, following a decision to stop development of Tamsulosin DRS, VERU-722 and VERU-112. R&D expense also rose to $16.9 million from $13.7 million.
- Year-end cash increased by $7.3 million, supported mainly by equity financing. Common shares outstanding increased during the year; the company also had an Aspire agreement permitting up to $23.9 million of additional stock purchases over its term.
Outlook, commentary and risks
- Management said existing cash and expected commercial-product cash generation were adequate to fund planned operations for the next 12 months, but anticipated continuing losses and substantial development spending. FY2021 R&D expense was expected to increase as multiple programs advanced.
- Management expected to begin the VERU-111 prostate-cancer Phase 3 study in Q1 2021 and the enobosarm breast-cancer Phase 3 study in H1 2021. A VERU-100 Phase 2 study was planned for early 2021; TADFYN’s NDA submission was expected in early 2021. These are forward-looking plans, not reported outcomes.
- VERU-111 was also in a Phase 2 COVID-19 study. The filing cautions that its development was early-stage, could divert resources from other programs, and might not produce an effective treatment or receive grant funding.
- Customer concentration is material: three customers accounted for 76% of FY2020 revenue, including one at 42%; three customers also represented 89% of net receivables at year-end. Large government tenders do not guarantee minimum purchases, and orders can fluctuate substantially.
- COVID-19 temporarily interrupted manufacturing at the company’s sole FC2 facility in Malaysia. Production resumed, but the company cited continuing exposure to facility, labor, shipping and raw-material disruption, including reliance on a single supplier for the nitrile sheath.
- Other principal risks include clinical and regulatory failure or delay, need for additional capital and potential dilution, competition and pricing pressure for FC2, intellectual-property and licensing risks, and the revenue-linked SWK financing obligations and covenants.
- Subsequent event: On December 8, 2020, Veru sold substantially all PREBOOST business assets for $20.0 million: $15.0 million at closing and $2.5 million due at each of 12 and 18 months. The company expected an after-tax gain of approximately $18.3 million and intended to use proceeds for working capital and general corporate purposes, including R&D.
Important facts for investors to verify
- Whether FC2 U.S. prescription growth and higher pricing can persist, and how public-health tenders, competition and customer concentration affect revenue and collections.
- Current cash, actual payments under the SWK credit and residual royalty agreements, and the company’s financing needs and potential equity dilution.
- Actual enrollment, timing, FDA interactions and results for the planned oncology trials and TADFYN NDA; the filing’s schedules are expectations only.
- Completion and collection of the PREBOOST sale’s deferred payments, and the realized gain and use of proceeds.
- Whether manufacturing and key-material supply remain reliable amid pandemic-related and single-facility risks.